羟丙基-β-环糊精作为注射给药的载体研究进展

被引:6
作者
罗恒 [1 ]
赵燕宜 [2 ]
杨明 [1 ]
机构
[1] 江西中医学院教育部重点实验室
[2] 中国医药科技出版社
关键词
羟丙基-β-环糊精; 注射给药; 载体; 综述;
D O I
暂无
中图分类号
R94 [药剂学];
学科分类号
100602 ; 100702 ;
摘要
引用
收藏
页码:68 / 70
页数:3
相关论文
共 8 条
[1]  
药物新剂型与新技术.[M].陆彬主编;.人民卫生出版社.1998,
[2]  
Development of parenteral formulation for a novel angiogenesis inhibitor; CKD-732 through complexation with hydroxypropyl-β-cyclodextrin.[J].Jae-Hyun Kim;Su-Kyung Lee;Min-Hyo Ki;Won-Kyu Choi;Soon-Kil Ahn;Hee-Jong Shin;Chung Il Hong.International Journal of Pharmaceutics.2004, 1
[3]   Kinetic study of a 2-hydroxypropyl-β-cyclodextrin-based formulation of all-trans-retinoic acid in Sprague-Dawley rats after oral or intravenous administration [J].
Lin, HS ;
Chan, SY ;
Low, KSY ;
Shoon, ML ;
Ho, PC .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 89 (02) :260-267
[4]   Comparison of the effects of potential parenteral vehicles for poorly water soluble anticancer drugs (organic cosolvents and cyclodextrin solutions) on cultured endothelial cells (HUV-EC) [J].
Medlicott, NJ ;
Foster, KA ;
Audus, KL ;
Gupta, S ;
Stella, VJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (09) :1138-1143
[5]   Inclusion complexation of propofol with 2-hydroxypropyl-β-cyclodextrin.: Physicochemical, nuclear magnetic resonance spectroscopic studies, and anesthetic properties in rat [J].
Trapani, G ;
Latrofa, A ;
Franco, M ;
Lopedota, A ;
Sanna, E ;
Liso, G .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (04) :514-518
[6]  
Safety of Parenteral Hydroxypropyl β ‐Cyclodextrin.[J].Thomas O. Carpenter;Andrea Gerloczy;Josef Pitha.Journal of Pharmaceutical Sciences.1995, 2
[7]  
Solubilization of Thiazolobenzimidazole Using a Combination of pH Adjustment and Complexation with 2-Hydroxypropyl-β-Cyclodextrin.[J].Abdi Y. Tinwalla;Barbara L. Hoesterey;Tian-xiang Xiang;Kap Lim;Bradley D. Anderson.Pharmaceutical Research.1993, 8
[8]   THE EFFECTS OF CYCLODEXTRINS ON THE DISPOSITION OF INTRAVENOUSLY INJECTED DRUGS IN THE RAT [J].
FRIJLINK, HW ;
FRANSSEN, EJF ;
EISSENS, AC ;
OOSTING, R ;
LERK, CF ;
MEIJER, DKF .
PHARMACEUTICAL RESEARCH, 1991, 8 (03) :380-384